Comparative Pharmacology
Head-to-head clinical analysis: IGALMI versus LUCEMYRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IGALMI versus LUCEMYRA.
IGALMI vs LUCEMYRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from the central nervous system, resulting in decreased agitation and sedation.
LUCEMYRA (lofexidine) is a central alpha-2 adrenergic agonist that reduces the release of norepinephrine in the brain, thereby alleviating opioid withdrawal symptoms.
Sublingual: 120 mcg to 180 mcg as a single dose, administered under the tongue, one time. Maximum single dose: 180 mcg.
18 mg orally 5-6 times daily (maximum 108 mg/day) for 7-14 days then tapered over 4-6 weeks.
None Documented
None Documented
Terminal elimination half-life is 2.5 to 3.5 hours in healthy subjects, with prolonged half-life in patients with hepatic impairment (up to 5-7 hours) or renal impairment (up to 6-8 hours).
Terminal half-life approximately 5-6 hours; no clinically significant accumulation with twice-daily dosing.
Approximately 75% of the dose is excreted renally as unchanged drug, with the remainder eliminated via biliary/fecal routes (approximately 20%) and minor metabolic clearance.
Renal: 63% as unchanged drug; fecal: 27% (mostly unchanged); biliary: minimal (<5%).
Category C
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist